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Summary Levels of the nucleotide pathway enzyme thymidine kinase (TK) were assayed in the mononuclear
leukocytes and serum of 70 female patients with breast cancer and 98 male and 77 female non-cancer hospital
patients. The total TK levels in both mononuclear leukocytes and serum from patients with breast cancer
were significantly higher than in controls. The serum TK levels showed a significant correlation with cancer
stage. No such correlation was observed with mononuclear leukocyte TK levels. Serum TK from 20 patients
with breast cancer and 19 control patients was further assayed to ascertain the relative contributions of the
thymidine kinase isozymes TK1 and TK2 to total TK levels. The increase in serum TK from breast cancer
patients appears to be due to an increase in both TKl and TK2 levels.
The pyrimidine nucleotide salvage pathway enzyme, thymi-
dine kinase (TK), occurs mainly in two forms in human
tissue (for review, see Kit, 1976). TKl is the cytosolar TK
and has high activity in dividing cells but is absent in resting
cells (Bello, 1974). This form of the enzyme has therefore
high activity in foetal and neoplastic tissue, but low activity
in non-growing adult tissue (Gordon et al., 1968; Machovich
& Greengard, 1972; Caron & Unsworth, 1978). The second
form of the enzyme, TK2, is of mitochondrial origin, and is
present in the mitochondrial matrix. TK2 activity remains
relatively constant throughout the cell cycle (Adler &
McAuslin, 1974). The two TK isozymes have different
biochemical properties. TKl migrates slowly during poly-
acrylamide gel electrophoresis while TK2 migrates rapidly
(Kit & Leung, 1974; Taylor et al., 1972). The two forms of
TK also differ in terms of pH optima, heat stability,
inhibition by dCTP and phosphate donor specificity (Taylor
et al., 1972). Both isozymes utilise ATP efficiently as phos-
phate donor with CTP resulting in relative decreases in
activity of approximately 85-90% for TKI and 7-30% for
TK2 (Taylor et al., 1972; Ellims et al., 1981a).
Total TK (i.e., TKl +TK2) levels have been found to be
elevated in the serum of rats bearing transplanted hepatomas
(Taylor et al., 1981). Kreis et al., (1982) found a substantial
increase in total TK levels in the plasma of mice with
advanced leukaemias and in humans with acute non-lympho-
cytic leukaemia, chronic myelocytic leukaemia, pancreatic
cancer (with metastasis to liver), fibrohistiocytoma, carcinoid
syndrome (with metastasis to bone), and prostate cancer
(with metastasis to bone). More recently it has been found
that there are elevations in serum total TK levels in patients
with non-Hodgkin's lymphoma and cancers of bone (metas-
tatic, primary site unknown), squamous cell, prostate, brain
and basal cell (O'Neill et al., 1986,1987). The increases in
serum total TK activities appear to be largely the result of
increased TKI levels (O'Neill et al., 1987). This is in
agreement with the observations of other workers who have
found elevated serum TKI levels in patients with adult non-
Hodgkin's lymphoma (Ellims et al., 1981b; Gronowitz et al.,
1983), acute lymphoblastic and non-lymphoblastic leukaemia
as well as chronic myelogenous leukaemia (Hagberg et al.,
1984), childhood acute lymphoblastic leukaemia (Morgan et
al., 1985), Hodgkin's lymphoma (Eriksson et al., 1985),
multiple myeloma (Simonsson et al., 1985) and secondary
brain tumours (Gronowitz et al., 1984). Mononuclear leuko-
cyte total TK levels have been found to be elevated in
cancers of thyroid and bladder (McKenna et al., 1985;
O'Neill et al., 1987).
The present communication describes a study of total TK
levels in mononuclear leukocytes and serum from 70 female
patients with breast cancer and 98 male and 77 female non-
cancer hospital patients. The study also includes an assess-
ment of the relative contributions of the TKI and TK2
isozymes to any increases observed in serum total TK levels.
Patients and methods
The patients with breast cancer (all from Belvoir Park
Hospital) had undergone surgery but had not at the time of
sampling undergone any form of treatment for cancer.
Patients were staged 1-4 depending on the stage of advance-
ment of the disease (American Joint Committee on Cancer,
1983). Control patients (from Coleraine Hospital) were
sampled from those scheduled to undergo surgery for a
variety of non-malignant conditions. Patients were enrolled
in the study over a period of two years.
Fifteen ml of peripheral venous blood was obtained, lOml
placed in a heparinised tube for mononuclear leukocyte
separation and the remainder in a Corvac serum separation
tube. Mononuclear leukocytes were separated as previously
described (McKenna et al., 1985).
Thymidine kinase assays were based on methods pre-
viously described (O'Neill et al., 1986; McKenna et al.,
1985). After separation the mononuclear leukocytes were
washed twice in Hank's BSS, were resuspended in 0.5ml of
extraction buffer containing 0.02M Tris (pH7.8) and 0.005M
mercaptoethanol, 0.005 M MgCl2 and 0.2 M KCl in a conical
polypropylene graduated tube. The cells were freeze-thawed
(liquid nitrogen to 37°C) three times and the lysate centri-
fuged for 30min at 30,000g. The supernatant fractions were
used as a source of soluble thymidine kinase extract for the
enzyme assay.
The assay mix consisted of 0.02 M Tris (pH 7.8), 2 x 10-6 M
3H thymidine (85 Cimmol1), 0.002 MMgCl2, 0.2 MKCl, 0.1 M
NH4Cl, 0.005 M mercaptoethanol and 0.002 M ATP. The
assay mix also contained 0.5 mgml- bovine serum albumin.
Tubes containing equal quantities of enzyme extract and
assay mix to a total volume of 0.3ml were incubated at 370C
in a water bath. After exactly 30min, 4 x 25p1 samples from
each tube were applied to Whatman diethylaminoethyl
(DEAE) cellulose (DE-81) paper discs. The discs were sub-
sequently washed three times (3 x 5min) in 0.001M ammo-
nium formate (1Oml/disc), washed in distilled water and
fixed in absolute ethanol. The dried discs were placed in
glass scintillation vials and counted in 5ml toluene based
scintillant containing Triton-X-100.
For serum TK assays, serum was added in equal quantity
to a total volume of 200M1 to the assay mix described above
and allowed to incubate for 60min before spotting on DE-81
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discs. The reaction for mononuclear leukocytes and serum
TK was linear for at least 90 min. There was < 10%
variation between duplicate assays.
A second assay mix was prepared containing CTP instead
of ATP as phosphate donor. This was used to measure the
relative contributions of the TKI and TK2 isozymes to total
TK activity (Ellims et al., 1981a).
Results
The mononuclear leukocyte total TK activities in patients
with breast cancer (all female) and female control patients
are presented in Figure 1. The breast cancer patients (n=70)
had a mean age of 57.15 years (+ 1.40 s.e.) and a mean
mononuclear leukocyte total TK activity of 13.01 +0.82pmol
dTMP 10-6 cells h-1. This activity was significantly higher
(P<0.05) than that found in female control patients (n=77)
who had a mean age of 39.92 + 1.97 and a mean mono-
nuclear leukocyte total TK activity of 10.25 +0.73 pmol
dTMP 10-6 cells h-1.
Although the breast cancer patients were significantly
older than control patients, it can be seen from Table I that
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neither age nor sex is a major determinant for mononuclear
leukocyte total TK activity. No significant difference
emerged between the male and female control patients either
overall or for any of the age bands. Only the 30-44 age band
yielded a statistically significant difference (P<0.05) between
the cancer patients and female controls. The mean mono-
nuclear leukocyte TK levels for each cancer stage (I-IV) are
presented in Table II. No statistical correlation exists
between TK levels and stage.
Serum total TK activities in breast cancer patients and
control females are presented in Figure 2. The breast cancer
patients has a mean serum total TK activity of 6.2+0.47
pmol dTMP ml- I h-1 which was significantly higher
(P<0.001) than that found in control females (3.69+0.20).
Neither age nor sex appears to be a significant deter-
minant of serum total TK activity. No significant overall
difference was found between the male and female control
patients, however in the >60 age category females were
found to have significantly higher (P<0.05) serum total
levels than males (Table III). Conversely this age category
did not show a significant difference between breast cancer
Table II Mononuclear leukocyte TK levels in relation to cancer
stage
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Figure 1 Mononuclear leukocyte total TK levels. Each point
represents a single patient. Mean values+s.e. are also indicated.
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Table I Mononuclear leukocyte TK levelsa in relation to age and
sex
Control Control Breast Cancer
Age band males females females
<29 9.55 + 1.05 11.71 +1.45
(n =28) (n =27) (n =0)
30-44 9.28+ 1.35 9.69+0.92 13.89+ 1.91
(n=25) (n=22) (n= 14)
45-59 11.40+2.56 7.99 + 1.61 12.71 +1.66
(n =26) (n = 15) (n =23)
.60 8.87+ 1.37 10.77+ 1.89 12.87+ 1.09
(n= 19) (n= 13) (n=33)
apmol dTMP 10-6 cells h-+s.e.
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Figure 2 Serum total TK levels.
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Table III Serum TK levelsa in relation to age and sex
Control Control Breast cancer
Age band males females females
<29 3.65+0.29 3.91 +0.38
(n=28) (n=27) (n=0)
30-44 4.68 +0.51 3.59+0.32 7.03 + 1.01
(n=25) (n=22) (n= 14)
45-59 3.71 +0.31 3.12+0.28 6.37+0.75
(n =26) (n = 15) (n =23)
>60 2.93+0.33 4.04+0.62 5.74+0.72
(n=19) (n=13) (n=33)
apmol dTMP ml-'h-'+s.e.
patients and control females whereas the 30-44 and 45-59
categories showed significant differences (P<0.001 and
P<0.01, respectively).
The relationship between serum total TK levels and cancer
stage is shown in Table IV. A significant positive correlation
(P<0.001) was found between TK levels and stage. Stage I
cancer patients showed similar serum total TK levels to
control females. While serum total TK levels from.stage II
patients were not significantly higher than stage I levels,
stage III patients had significantly higher (P<0.05) levels
than stage II and stage IV patients had significantly higher
(P<0.05) levels than stage III patients.
The relative contributions of the two forms of TK, namely
TK1 and TK2, to total TK levels in serum were assessed
using ATP- and CTP-containing assay mixes. The % CTP/
ATP TK levels in serum of a sample of 20 patients with
breast cancer and 19 female control patients are shown in
Table V.
It can be seen that the mean % CTP/ATP TK activity in
the breast cancer patients (62.7%) is similar to that found in
the control patients (64.2%). This indicates that the propor-
tions of TK1 and TK2 are similar in both groups of patients
and the relative increase in serum total TK activity found in
breast cancer patients is likely to be due to an increase in
serum levels of both forms of TK.
Table IV Serum TK levels in relation to cancer stage
Serum TK activity
Cancer Mean age (pmoldTMPml-l h-1)
Patients stage (Yr+s.e.) +s.e.
Control 39.92+ 1.97 3.69+0.20
females (n =77)
Breast I 51.66+4.71 3.55+0.64
cancer (n =9)
patients II 57.16+1.68 5.16+0.47
(all female) (n= 36)
III 59.87+3.42 7.30+ 1.07
(n = 16)
IV 57.7+4.05 11.12+1.32
(n =9)
Table V Serum TK levels using ATP/CTP as phosphate donor
Serum TK activity
Mean age (pmoldTMPml h ±+s.e.) %CTP/ATP
Patients (Yr+s.e.) ATP CTP TK activity
Control
females
(n= 19) 29.31+2.64 3.60+0.35 2.31+0.21 64.2
Breast
cancer
females
(n=20) 60.85+2.63 5.57+0.68 3.49+0.53 62.7
Discussion
The results indicate that total TK levels are significantly
elevated in mononuclear leukocytes and serum from patients
with breast cancer. Serum total TK levels are also correlated
with the stage of advancement of the disease. This obser-
vation is in agreement with earlier work where a relationship
was found between serum TK1 levels and cancer stage and
prognosis in patients with non-Hodgkin's and Hodgkin's
lymphoma (Gronowitz et al., 1983; Eriksson et al., 1985) and
between serum TKI levels and prognosis in patients with
acute myelogenous leukaemia (Hagberg et al., 1984), chronic
lymphocytic leukaemia (Kallander et al., 1984) and multiple
myeloma (Simonsson et al., 1985).
The serum TK activities obtained using CTP instead of
ATP as phosphate donor indicate that the increase in serum
total TK levels in breast cancer patients over controls is due
to an increase in both TKI and TK2 since the % CTP/ATP
TK activity does not differ substantially between the two
groups. Kreis et al. (1982) suggested that enhanced plasma
TK levels in patients and mice with cancer may be a result
of the release of TK into the peripheral blood circulation
from tumour cells. This is supported by the finding that
rapidly proliferating tumour cells in culture release TK into
the surrounding medium (Bristow et al., 1988). The results
described in the present communication would also corres-
pond with the tumour cells being the source of the elevated
serum TK levels since Sakamoto et al. (1986) has reported
that both isozyme forms of TK are elevated in human
mammary tumours with TKI showing the greater increase in
activity.
The increase in total TK levels in mononuclear leukocytes
is unlikely to be related to the increase in serum TK levels.
Mononuclear leukocyte TK levels, unlike serum TK, are not
correlated with the stage of advancement of the disease.
Whatever the underlying mechanisms it would appear that
breast cancer is associated with elevated TK levels in serum
and mononuclear leukocytes and measurement of the dis-
ease. Work is currently underway to ascertain its usefulness
as a prognostic indicator.
We acknowledge the cooperation of Mr T.E.B. Dane, Dr W.J. Love
and Dr K. Fitzpatrick. This research was funded by The Ulster
Cancer Foundation.
References
ADLER, R. & McAUSLIN, B.R. (1974). Expression of thymidine
kinase variants is a function of the replicative state of cells. Cell,
2, 113.
AMERICAN JOINT COMMITTEE ON CANCER (1983). Manual for
staging of cancer (2nd ed) Lippincott: Philadelphia.
BELLO, L.J. (1974). Regulation of thymidine kinase synthesis in
human cells. Exptl Cell. Res., 89, 263.
BRISTOW, H., O'NEILL, K.L., HANNIGAN, B.M. & McKENNA, P.G.
(1988). Leakage of thymidine kinase from proliferating cells.
Biochem. Soc. Trans., (in press).
CARON, P. & UNSWORTH, B. (1978). Alteration of the activity and
molecular form of thymidine kinase during development and
ageing in the mouse cerebellum. Mech. Age. Dev., 8, 181.
ELLIMS, P.H., VAN DER WEYDEN, M.B. & MEDLEY, G. (1981a).
Thymidine kinase isoenzymes in malignant lymphoma. Cancer
Res., 41, 691.
ELLIMS, P.H., ENG GAN, T., MEDLEY, G. & VAN DER WEYDEN, M.B.
(1981b). Prognostic relevance of thymidine kinase isozymes in
adult non-Hodgkin's lymphoma. Blood, 58, 926.
ERIKSSON, B., HAGBERG, H., GLIMELIUS, B & 3 others (1985).
Evaluation of serum deoxythymidine kinase as a marker in
multiple myeloma. Br. J. Haematol., 61, 215.622 P.G. McKENNA et al.
GORDON, H.L., BARDOW, T.J., CHMIDEWICZ, A.F. & AMBRUS, J.L.
(1968). Comparative study of the thymidine kinase and the
thymidylate kinase activities and of the feedback inhibition of
thymidine kinase in normal and neoplastic human tissue. Cancer
Res., 28, 2068.
GRONOWITZ, J.S., HAGBERG, H., KALLANDER, C.F.R. &
SIMONSSON, B. (1983). The use of serum deoxythymidine kinase
as a prognostic marker, and in the monitoring of patients with
non-Hodgkin's lymphoma. Br. J. Cancer, 47, 487.
GRONOWITZ, J.S., KALLANDER, C.F.R., HAGBERG, H. & PERSSON,
L. (1984). Deoxythymidine kinase in cerebrospinal fluid: A new
potential marker for brain tumours. Acta Neurochirurgica, 73, 1.
HAGBERG, H., GRONOWITZ, S., KILLANDER, A. & 4 others (1984).
Serum thymidine kinase in acute leukaemia. Br. J. Cancer, 49,
537.
KALLANDER, C.F.R., SIMONSSON, B., HAGBERG, H. &
GRONOWITZ, J.S. (1984). Serum deoxythymidine kinase gives
prognostic information in chronic lymphocytic leukaemia. Cancer,
54, 2450.
KIT, S. & LEUNG, W.-C. (1974). Sub-mitochondrial localisation and
characteristics of thymidine kinase molecular forms in parental
and kinase-deficient HeLa cells. Biochem. Genet., 231.
KIT, S. (1976). Thymidine kinase, DNA synthesis and cancer. Mol.
Cell. Biochem., 11, 161.
KREIS, W., ARLIN, Z., YAGODA, A., LEYLAND JONES, B.R. & FIORI,
L. (1982). Deoxycytidine and deoxythymidine kinase activities in
plasma of mice and patients with neoplastic disease. Cancer Res.,
42, 2514.
MACHOVICH, K. & GREENGARD, 0. (1972). Thymidine kinase in
rat tissues during growth and differentiation. Biochim. Biophys.
Acta, 286, 375.
McKENNA, P.G., O'NEILL, K.L. & ABRAM, W.P. (1985). Elevated
thymidine kinase levels in mononuclear leukocytes of cancer
patients J. Clin. Hematol. Oncol., 15, 71.
MORGAN, M.A.M., COOPER, E.H., BAILEY, C.C. & 2 others (1985).
Serum deoxythymidine kinase in acute lymphoblastic leukaemia
in children. Tumor Diagnostik & Therapie, 6, 155.
O'NEILL, K.L., ABRAM, W.P. & McKENNA, P.G. (1986). Serum
thymidine kinase levels in cancer patients. Ir. J. Med. Sci., 155,
272.
O'NEILL, K.L., ABRAM, W.P., HANNIGAN, B.M. & McKENNA, P.G.
(1987). Elevated serum and mononuclear leukocyte thymidine
kinase activities in patients with cancer. Ir. Med. J., 80, 264.
SAKAMOTO, S., IWAMA, T., EBUCHI, M. & 7 others (1986). Increased
activities of thymidine kinase isozymes in human mammary
tumours. Br. J. Surg., 73, 272.
SIMONSSON, B., KALLANDER, C.F.R., BRENNING, G. & 3 others
(1985). Evaluation of serum deoxythymidine kinase as a marker
in multiple myeloma. Br. J. Haematol., 61, 215.
TAYLOR, A.T., STAFFORD, M.A. & JONES, O.W. (1972). Properties of
thymidine kinase partially purified from human fetal and adult
tissue. J. Biol. Chem., 247, 1930.
TAYLOR, A., JONES, O.W. & GRISHAVER, M.A. (1981). Effect of 5-
fluorouracil on the release of thymidine kinase from hepatoma
cells in vitro. Cancer Res., 41, 192.